Immunic Shares up 23.2% Premarket After Co Reports Interim Late-Stage Study Data for Experimental Multiple Sclerosis Drug
Immunic公司報告實驗性多發性硬化症藥物的中期晚期研究數據後,盤前股價上漲23.2%
Immunic Shares up 23.2% Premarket After Co Reports Interim Late-Stage Study Data for Experimental Multiple Sclerosis Drug
Immunic公司報告實驗性多發性硬化症藥物的中期晚期研究數據後,盤前股價上漲23.2%
譯文內容由第三人軟體翻譯。